Influenza

A discussion on the lifting of COVID-19 restrictions and the potential impact on the upcoming flu season.

Panel speculates on the upcoming flu season for 2021-2022.

Multiple factors contributing to a lower-than-average flu season in 2020-2021 are discussed.

While the COVID-19 pandemic has helped advance respiratory diagnostics and surveillance, there are still many gaps that remain across the spectrum of healthcare.

A look at the COVID-19 driven factors for this upcoming influenza season, from reopening classrooms to reduced mutation chances.

A conversation with William Schaffner, MD.

The study was the largest of its kind looking at the flu shot and COVID-19.

FluGen announced its vaccine candidate, Bris2007 M2SR, induced neutralizing antibodies against infection and illness following a challenge with an antigenically distinct virus.

A clinical decision support (CDS) strategy including a default influenza vaccine order for eligible patients, a nursing script using a presumptive strategy, and education for clinicians, was associated with significant improvement in vaccination rates among hospitalized children, a new study showed.

Last influenza season was notably quiet during peaking COVID-19 cases. Experts explain what may influence risk of dueling epidemics this year.

A group of personnel at a veterans administration medical center (VAMC)) did a drive-thru to help bolster vaccination amongst coworkers.

The company’s mRNA-1010 is a seasonal influenza vaccine candidate that is targeting A H1N1, H3N2, influenza B Yamagata, and Victoria lineages.

Seqirus is seeking reactogenicity and immunogenicity outcomes between its influenza vaccines and available mRNA vaccines for COVID-19.

Plus: how could the COVID-19 testing market boom improve public flu awareness?

COVID-19 response restrained flu outbreaks last year. An expert explains his concern that won't be enough this winter.

An interview with a study author on new Novavax-Seqirus co-administration trial data, and the future concerns of circulating COIVD-19 and influenza.

The device may help clinicians differentiate between past infections and co-infections during the upcoming flu season.

In a population-based cohort study with a mean follow-up of 3.6 years, childhood outcomes showed no statistically significant associations with any adverse health conditions.

A discussion with the CDC’s Flu Czar, Lynnette Brammer, surrounding the upcoming flu season and what we can expect due to the COVID-19 pandemic.

The government agency will be assessing the safety and immunogenicity of an investigational nanoparticle influenza vaccine.

A concerted effort to increase flu vaccination during the COVID-19 pandemic resulted in more protection among a high-risk population, as well as educational opportunities for pharmacy students.

NanoFlu/NVX-CoV2373 elicited functional influenza and COVID-19 antibodies in ferrets 2 weeks after vaccination.

The frontline assay from Abbott will help differentiate among 4 respiratory viruses in real-time.

The authors note that the difference in hospitalization rate may be partly due to existing immunity to influenza in the population.

Investigators are calling for routine use of these tests for patients admitted with acute respiratory symptoms during the influenza season.

New study may help contribute to COVID-19 research.

A recently created therapy for the influenza virus may help aid in the fight against COVID-19.

The new pathogen panel will distinguish between 20 different common and serious respiratory infections, giving clinicians more confidence in flu season diagnoses.

In a national survey, parents responded they would not be getting a vaccine for their kids during the COVID-19 pandemic.

This test simultaneously detects and differentiates between SARS-CoV-2, influenza A and B.